Answers are grounded in this paper and cite their sources.
The advent of next-generation incretin therapies has revolutionized the management of obesity and cardiometabolic diseases, achieving significant and historically unprecedented weight reductions in pharmacotherapy. However, the commercial appeal and aesthetic pressure from social media have transformed these medications into short-term body remodeling tools, creating a false perception of a "definitive solution" and diverting attention from the need for long-term management. This opinion article examines the global impact of these therapies and critiques the lack of clinical guidelines addressing the postachievement phase of therapeutic goals. Abrupt discontinuation or loss of follow-up triggers compensatory neuroendocrine adaptations, resulting in weight cycling and the development of sarcopenic obesity due to disproportionate regain of visceral fat. It is concluded that obesity management should not stop at the peak phase of treatment. The implementation of structured deprescribing protocols (gradual tapering) co-managed by the endocrinologist and the clinical pharmacist, integrated into the interdisciplinary team, is advocated, transforming discontinuation into an active and safe step for the continuous maintenance of cardiometabolic health.
No takes yet. Share an insight, caveat, or question.
João Pedro FD (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: